Cresco Labs (CRLBF) P/S Ratio
Cresco Labs (CRLBF) has a price-to-sales ratio of 0.33x, placing it in the Deep Value range for cannabis stocks. The company has a market cap of $213.9M and TTM revenue of $655.8M. Revenue is declining 9.5% YoY.
P/S Ratio (TTM)
0.33x
EV/Revenue
0.84x
Market Cap
$213.9M
Revenue Growth
-9.5%
Valuation Breakdown
| Metric | Value |
|---|---|
| Stock Price | $0.61 |
| Market Capitalization | $213.9M |
| TTM Revenue | $655.8M |
| Price-to-Sales (TTM) | 0.33x |
| EV/Revenue | 0.84x |
| Revenue Growth (YoY) | -9.5% |
| Gross Margin | 49.5% |
| Sector | MSO |
| Exchange | OTC |
| Valuation Range | Deep Value |
Frequently Asked Questions
What is CRLBF's current price-to-sales ratio?+
The price-to-sales (P/S) ratio divides Cresco Labs's market capitalization by its trailing twelve months of revenue. Since many cannabis companies are not yet profitable, P/S is one of the most widely used valuation metrics in the sector. A lower ratio may suggest the stock is undervalued relative to revenue.
How does CRLBF's P/S compare to other cannabis stocks?+
P/S ratios in cannabis typically range from 0.5x to 5x depending on growth rate, profitability, and market sentiment. High-growth companies command higher multiples, while mature, lower-growth companies trade at lower multiples. Compare Cresco Labs to peers in the same sub-sector (MSO, LP, ancillary) for meaningful context.
Is CRLBF overvalued or undervalued based on P/S?+
A single metric like P/S cannot definitively determine if Cresco Labs is over- or undervalued. Consider P/S alongside revenue growth rate, gross margins, cash position, and competitive dynamics. A company growing revenue at 50% YoY may justify a higher P/S than one growing at 5%. Also consider enterprise value-to-revenue (EV/Revenue) which accounts for debt and cash.